Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma

Modern Pathology

Volumn 21, Issue 10, 2008, Pages 1224-1237

  Choi, Young J ^a   Pinto, Marguerite M ^a   Hao, Liming ^a   Riba, Ali K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aberrant immunoreaction; E cadherin expression; Interobserver variability; Lobular neoplasia

Indexed keywords

ANTIBODY; PARAFFIN; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST LESION; CANCER DIAGNOSIS; CANCER INFILTRATION; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MORPHOLOGY; OBSERVER VARIATION; PRIORITY JOURNAL; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 52549126484     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.106     Document Type: Article

References (58)

1. Foote FW, Stewart FW. Lobular carcinoma in situ. A rare form of mammary cancer. Am J Pathol 1941;17:491-499.
2. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737-769.
3. Rogers LW. Carcinoma in situ (CIS). In: Page DL, Anderson TJ (eds). Diagnostic Histopathology of the Breast. Churchill Livingston: New York, NY, 1987, pp 157-197.
4. Rosen PP. Lobular carcinoma in situ and atypical lobular hyperplasia In: Rosen's Breast Pathology, 2nd edn. Lippincott William & Wilkins: Philadelphia, PA, 2001, pp 581-626.
5. Schnitt SJ, Morrow M. Lobular carcinoma in situ: current concepts and controversies. Sem Diag Pathol 1999;16:209-223.
6. Tavassoli FA. Lobular neoplasia In: Tavassoli FA (ed). Pathology of the Breast, 2nd edn. McGraw-Hill: New York, NY, 1999, pp 373-400.
7. Rosen PP. Coexistent lobular carcinoma in situ and intraductal carcinoma in a single lobular-duct unit. Am J Surg Pathol 1980;4:241-246.
8. Fadare O, Dadmanesh F, Alvarado-Cabrero I, et al. Lobular intraepithelial neoplasia (lobular carcinoma in situ) with comedo-type necrosis: a clinicopathologic study of 18 cases. Am J Surg Pathol 2006;30:1445-1453.
9. Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch 2001;440:134-138.
10. Koerner F, Maluf H. Uncommon morphologic pattern of lobular neoplasia. Ann Diag Pathol 1999;4:249-259.
11. Arpino G, Bardou VJ, Clark GM, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:149-156.
12. Molland JG, Donnellan M, Janu NC, et al. Infiltrating lobular carcinoma - a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004;13:389-396.
13. Peiro G, Bornstein BA, Connolly JL, et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2000;59:49-54.
14. Siitonen SM, Kononen JT, Helin HJ, et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996;105:394-402.
15. Acs G, Lawton TJ, Rebbeck TR, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98.
16. Goldstein NS, Bassi D, Watts JC, et al. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001;115:534-542.
17. Wheeler DT, Tai LH, Bratthauer GL, et al. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol 2004;28:1587-1593.
18. Rakha EA, Rehim AE, Pinder SE, et al. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005;46:685-693.
19. Qureshi HS, Linden MD, Divine G, et al. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol 2006;125:377-385.
20. Kuroda H, Tamaru J, Takeuchi I, et al. Expression of E-cadherin, α-catenin, and β-catenin in tubulolobular carcinoma of the breast. Virchows Arch 2006;448:500-505.
21. Jacobs TW. Recently recognized variants of lobular carcinoma in situ (LCIS) with an emphasis of management of LCIS on core needle biopsy. Pathol Case Rev 2003;8:211-219.
22. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinoma. Am J Pathol 1993;143:1731-1742.
23. Asgeirsson KS, Jonasson JG, Tryggvadottir L, et al. Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer 2000;36:1098-1106.
24. Goldstein NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001;92:738-747.
25. Maluf HM, Swanson PE, Koerner FC. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol 2001;25:237-244.
26. Jacobs TW, Pliss N, Kouria G, et al. Carcinomas in situ of the breast with indeterminate features. Role of E-cadherin staining in categorization. Am J Surg Pathol 2001;25:229-236.
27. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am J Clin Pathol 2002;118:425-434.
28. Wahed A, Connelly J, Reese T. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma. Ann Diag Pathol 2002;6:349-351.
29. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:R217-R222.
30. Kovacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. BMJ 2003;56:318-322.
31. Harigopal M, Shin SJ, Murray MP, et al. Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol 2005;3:73-85.
32. Bukholm IK, Nesland JM, Karesen R, et al. E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998;185:262-266.
33. Charpin C, Garcia S, Bonnier P, et al. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 1997;109:431-438.
34. Oka H, Shizaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-1701.
35. Yoshida R, Kimura N, Harada Y, et al. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive carcinoma. Int J Oncol 2001;18:513-520.
36. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of co-existence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;31:417-426.
37. Lehr HA, Folpe A, Yaziji H, et al. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000;114:190-196.
38. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-411.
39. Hashizume R, Koizumi H, Ihara A, et al. Expression of β-catenin in normal breast tissue and breast carcinoma: a comparative study with epithelial cadherin and α-catenin. Histopathology 1996;29:139-146.
40. Oyama T, Kanai TY, Ochiai A, et al. A truncated β-catenin disrupts the interaction between E-cadherin and α-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994;54:6283-6287.
41. Ozawa M, Kemler R. Altered cell adhesion activity by pervanadate due to the dissociation of α-catenin from the E-cadherin-catenin complex. J Biol Chem 1998;273:6166-6170.
42. Steinberg MS, McNutt PM. Cadherins and their connections: adhesion junctions have broader functions. Curr Opin Cell Biol 1999;11:554-560.
43. Zschiesche W, Schpnborn I, Behrens J, et al. Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 1997;17:561-568.
44. Hwang ES, Nyante SJ, Chen YY, et al. Clonality of lobular carcinomas in situ and synchronous invasive lobular carcinoma. Cancer 2004;100:2562-2572.
45. Kanai Y, Oda T, Tsuda H, et al. Point mutation of the E-cadherin gene in invasive carcinomas of the breast. Jpn J Cancer Res 1994;85:1035-1039.
46. Lerwill MF. The evolution of lobular neoplasia. Adv Anat Pathol 2006;13:157-165.
47. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDHI genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003;106:208-215.
48. Stange D, Radiwimmer B, Schubert F, et al. High-resolution genomic profiling reveals association ion of chromosomal aberration on 1q and 16 p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006;12:345-352.
49. Xiaodong JI, Woodward AJ, Rimm DL, et al. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 1997;8:773-778.
50. Caldeira JR, Prando EC, Quevedo FC, et al. CDH1 promotor hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006;6:48-60.
51. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-5199.
52. Vos CBJ, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997;76:1131-1133.
53. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48.
54. Brogi E, Oyama T, Koerner F. Atypical cystic lobules in patients with lobular neoplasia. Int J Surg Pathol 2001;9:201-206.
55. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-1925.
56. Bratthauer GL, Moinfar F, Stamatakos MD, et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal and hybrid mammary epithelial neoplasias. Human Pathol 2002;33:620-627.
57. Korkola JE, De Vries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-7175.
58. Bempt IV, Vanhentenrijk V, Drijkoningen M, et al. Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes. J Pathol 2006;208:486-494.